- Admin
- #1
GeneTether Therapeutics Inc. ("GeneTether" or the "Company"), an innovative genetic medicines company focused on developing gene editing therapies to increase the correction efficiency of targeted genome editing technologies, announces that it has filed a preliminary prospectus (the "Preliminary Prospectus") for a proposed initial public offering (the "Offering") of units of the Company (the "Units"). In addition, the Company obtained a receipt for the Preliminary Prospectus with the securities